BlackRock Advisors’s Osiris Therapeutics, Inc. Common Stock OSIR Stock Holding History

BlackRock Advisors’s Portfolio OSIR Stock Details OSIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$43K	Buy	8,757 +295	+3%	+$1.51K	﹤0.01%	3297
2016 Q3	$42K	Sell	8,462 -81	-0.9%	-$415	﹤0.01%	3302
2016 Q2	$43K	Hold	8,543	–	–	﹤0.01%	3264
2016 Q1	$49K	Buy	8,543 +792	+10%	+$5.53K	﹤0.01%	3171
2015 Q4	$80K	Sell	7,751 -69,279	-90%	-$940K	﹤0.01%	3025
2015 Q3	$1.42M	Sell	77,030 -18,097	-19%	-$349K	﹤0.01%	1491
2015 Q2	$1.85M	Buy	95,127 +73,578	+341%	+$1.3M	﹤0.01%	1307
2015 Q1	$379K	Buy	21,549 +10,970	+104%	+$184K	﹤0.01%	2285
2014 Q4	$169K	Sell	10,579 -705	-6%	-$9.44K	﹤0.01%	2737
2014 Q3	$142K	Sell	11,284 -961	-8%	-$13.7K	﹤0.01%	2811
2014 Q2	$191K	Sell	12,245 -1,058	-8%	-$15.6K	﹤0.01%	2663
2014 Q1	$175K	Buy	13,303 +1,726	+15%	+$27K	﹤0.01%	2726
2013 Q4	$186K	Buy	11,577 +1,005	+10%	+$16K	﹤0.01%	2702
2013 Q3	$176K	Buy	10,572 +199	+2%	+$2.94K	﹤0.01%	2632
2013 Q2	$104K	Buy	+10,373	New	+$109K	﹤0.01%	2880

Other funds holding OSIR

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock Advisors's OSIR Position: Q4 2016 in Review

BlackRock Advisors increased its Osiris Therapeutics, Inc. Common Stock (OSIR) stake by 3.5% in Q4 2016, buying an estimated $1.51K and bringing the position to 8,757 shares worth $43K. The position accounts for ﹤0.01% of the portfolio, ranked #3297.

BlackRock Advisors first reported a position in OSIR in Q2 2013 and has held it in 15 quarters since. The position peaked at $1.85M in Q2 2015. 64 funds tracked by Wall St. Rank hold OSIR as of Q4 2016.

BlackRock Advisors held 8,757 shares of Osiris Therapeutics, Inc. Common Stock worth $43K as of Q4 2016.
BlackRock Advisors bought 295 Osiris Therapeutics, Inc. Common Stock shares in Q4 2016, an estimated $1.51K.
Osiris Therapeutics, Inc. Common Stock made up ﹤0.01% of BlackRock Advisors's portfolio in Q4 2016, its #3297 holding.
BlackRock Advisors first reported a position in Osiris Therapeutics, Inc. Common Stock in Q2 2013 and has held it in 15 quarters since.
BlackRock Advisors's Osiris Therapeutics, Inc. Common Stock position peaked at $1.85M in Q2 2015.
64 funds tracked by Wall St. Rank held Osiris Therapeutics, Inc. Common Stock as of Q4 2016.

Based on BlackRock Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.